KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+24.7%
5Y CAGR+42.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+24.7%/yr
Annual compound
5Y CAGR
+42.8%/yr
Recent deceleration
Percentile
P92
Near historical high
vs 5Y Ago
5.9x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 114.24% |
| 2024 | 77.41% |
| 2023 | 15.69% |
| 2022 | 58.96% |
| 2021 | 27.69% |
| 2020 | 19.25% |
| 2019 | 23.29% |
| 2018 | -20.71% |
| 2017 | 321.30% |
| 2016 | 64.99% |